M A Cenci
Overview
Explore the profile of M A Cenci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fieblinger T, Zanetti L, Sebastianutto I, Breger L, Quintino L, Lockowandt M, et al.
Sci Rep
. 2018 Jul;
8(1):10068.
PMID: 29968767
Dendritic regression of striatal spiny projection neurons (SPNs) is a pathological hallmark of Parkinson's disease (PD). Here we investigate how chronic dopamine denervation and dopamine replacement with L-DOPA affect the...
2.
Iderberg H, McCreary A, Varney M, Kleven M, Koek W, Bardin L, et al.
Exp Neurol
. 2015 Jun;
271:335-50.
PMID: 26037043
L-DOPA is the gold-standard treatment for Parkinson's disease (PD), but induces troublesome dyskinesia after prolonged treatment. This is associated with the 'false neurotransmitter' conversion of L-DOPA to dopamine by serotonin...
3.
Iderberg H, McCreary A, Varney M, Cenci M, Newman-Tancredi A
Neuropharmacology
. 2015 Feb;
93:52-67.
PMID: 25645393
Serotonin 5-HT1A receptor agonists reduce L-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease (PD). Here, we compared the effects of novel 5-HT1A receptor 'biased agonists' on LID in hemiparkinsonian...
4.
Brehm N, Bez F, Carlsson T, Kern B, Gispert S, Auburger G, et al.
Mol Neurobiol
. 2014 Oct;
52(3):1152-1164.
PMID: 25307288
Alpha-synuclein (SNCA) protein aggregation plays a causal role in Parkinson's disease (PD). The SNCA protein modulates neurotransmission via the SNAP receptor (SNARE) complex assembly and presynaptic vesicle trafficking. The striatal...
5.
Lindgren H, Rylander D, Iderberg H, Andersson M, OSullivan S, Williams D, et al.
J Parkinsons Dis
. 2013 Aug;
1(4):347-57.
PMID: 23933656
The transcription factor ΔFosB is a mediator of maladaptive neuroplasticity in animal models of Parkinson's disease (PD) and L-DOPA-induced dyskinesia. Using an antibody that recognizes all known isoforms of FosB...
6.
Cenci M, Ohlin K, Odin P
CNS Neurol Disord Drug Targets
. 2011 Aug;
10(6):670-84.
PMID: 21838677
Dyskinesia and motor fluctuations affect up to 90% of patients with Parkinson's disease (PD) within ten years of L-DOPA pharmacotherapy, and represent a major challenge to a successful clinical management...
7.
Lopes J, Arantes O, Cenci M
Braz J Biol
. 2010 Dec;
70(4):1109-13.
PMID: 21180922
The aim of this study was to determine the potency (ITU) and efficacy of a liquid formulation of Bacillus thuringiensis israelensis developed by the State University of Londrina named BioUel,...
8.
Lane E, Vercammen L, Cenci M, Brundin P
Exp Neurol
. 2009 Apr;
219(1):355-8.
PMID: 19393238
In some patients, graft-induced dyskinesia develops following intrastriatal transplantation of embryonic neural tissue for the treatment of Parkinson's disease. The mechanisms underlying these involuntary movements need to be clarified before...
9.
Lane E, Soulet D, Vercammen L, Cenci M, Brundin P
Neurobiol Dis
. 2008 Aug;
32(2):220-8.
PMID: 18675359
The observation that neural grafts can induce dyskinesias has severely hindered the development of a transplantation therapy for Parkinson's disease (PD). We addressed the hypothesis that inflammatory responses within and...
10.
Cenci M, Lindgren H
Curr Opin Neurobiol
. 2008 Mar;
17(6):665-71.
PMID: 18308560
The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disorders caused by either a deficiency or a hyperactivity of dopaminergic transmission in the...